A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormonreceptor Positive|Her2-normal|Postneoadjuvant Treatment With CDK 4/6 Inhibitor|CPS-EG Score
Interventions: DRUG: Palbociclib PD-0332991|DRUG: Placebo
Sponsor: German Breast Group
Collaborators: Pfizer|AGO Study Group|NSABP Foundation Inc|Breast International Group